Article · 20 May 2025
Review articlePublished 22 Jul 2016
Maintenance therapies in advanced non-small-cell lung cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Advanced non-small-cell lung cancer is treated with upfront platinum doublet chemotherapy, which produces moderate survival improvements. Unfortunately, many patients quickly progress after first-line therapy and become unable or ineligible for additional therapies. In the past, treatment beyond four to six cycles of cytotoxic therapy was not recommended owing to lack of benefit and increased toxicity. The purpose of maintenance therapy is to provide an acceptably well-tolerated therapy, allowing patients to maintain a high quality of life with an improved survival. Maintenance therapy with cytotoxic agents such as gemcitabine or docetaxel has provided an advantage in progression-free survival but at the expense of increased cumulative toxicity. However, newer cytotoxic agents, such as pemetrexed, and biologics, such as erlotinib, bevacizumab and cetuximab, have resulted in improved patient overall survival and have offered patients manageable toxicity profiles.
Keywords
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Practice.
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 28 Mar 2025
Using
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Daniel J Lebovic”
- BylineArticles whose byline prints “Alberto Chiappori”
- BylineArticles whose byline prints “Jhanelle Gray”